Hypomethylation of the lncRNA SOX21-AS1 has clinical prognostic value in cervical cancer

Wang, Ruijie; Li, Ya; Du, Peipei; Zhang, Xiaoan; Li, Xiaofu; Cheng, Guangming

doi:10.1016/j.lfs.2019.116708

Cited by 34 publications

(20 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, LINC01133 expression was positively correlated with the LINC01133 copy number in HCC samples, suggesting that LINC01133 increased copy number is at least partially responsible for the frequent LINC01133 upregulation in HCC. A previous study reported that hypomethylation of lncRNA genes may have an effect on increased expression of lncRNAs such as SOX21‐AS1 in cervical cancer 28 . Hence, the increased LINC01133 expression observed in our study might be caused by DNA hypomethylation in addition to copy number gains.…”

Section: Discussionmentioning

confidence: 47%

“…A previous study reported that hypomethylation of lncRNA genes may have an effect on increased expression of lncRNAs such as SOX21-AS1 in cervical cancer. 28 Hence, the increased LINC01133 expression observed in our study might be caused by DNA hypomethylation in addition to copy number gains. Furthermore, LINC01133 CNV gain was predictive of early HCC recurrence and poor prognosis after curative surgery.…”

Section: Discussionmentioning

confidence: 61%

See 1 more Smart Citation

LINC01133 promotes hepatocellular carcinoma progression by sponging miR‐199a‐5p and activating annexin A2

Yin

Luo

et al. 2021

Clinical & Translational Med

View full text Add to dashboard Cite

Background Long noncoding RNAs (lncRNAs) are functionally associated with cancer development and progression. Although gene copy number variation (CNV) is common in hepatocellular carcinoma (HCC), it is not known how CNV in lncRNAs affects HCC progression and recurrence. We aimed to identify a CNV‐related lncRNA involved in HCC progression and recurrence and illustrate its underlying mechanisms and prognostic value. Methods We analyzed the whole genome sequencing (WGS) data of matched cancerous and noncancerous liver samples from 49 patients with HCC to identify lncRNAs with CNV. The results were validated in another cohort of 238 paired HCC and nontumor samples by TaqMan copy number assay. We preformed Kaplan‐Meier analysis and log‐rank test to identify lncRNA CNV with prognostic value. We conducted loss‐ and gain‐of‐function studies to explore the biological functions of LINC01133 in vitro and in vivo. The competing endogenous RNAs (ceRNAs) mechanism was clarified by microRNA sequencing (miR‐seq), quantitative real‐time PCR (qRT‐PCR), western blot, and dual‐luciferase reporter assays. We confirmed the binding mechanism between lncRNA and protein by RNA pull‐down, RNA immunoprecipitation, qRT‐PCR, and western blot analyses. Results Genomic copy numbers of LINC01133 were increased in HCC, which were positively related with the elevated expression of LINC01133. Increased copy number of LINC01133 predicted the poor prognosis in HCC patients. LINC01133 overexpression in HCC cells promoted proliferation and aggressive phenotypes in vitro, and facilitated tumor growth and lung metastasis in vivo, whereas LINC01133 knockdown had the opposite effects. LINC01133 sponged miR‐199a‐5p, resulting in enhanced expression of SNAI1, which induced epithelial‐to‐mesenchymal transition (EMT) in HCC cells. In addition, LINC01133 interacted with Annexin A2 (ANXA2) to activate the ANXA2/STAT3 signaling pathway. Conclusions LINC01133 promotes HCC progression by sponging miR‐199a‐5p and interacting with ANXA2. LINC01133 CNV gain is predictive of poor prognosis in patients with HCC.

show abstract

Section: Discussionmentioning

confidence: 47%

Section: Discussionmentioning

confidence: 61%

LINC01133 promotes hepatocellular carcinoma progression by sponging miR‐199a‐5p and activating annexin A2

Yin

Luo

et al. 2021

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…In gastric cancer, lncRNA MAGI2-AS3 was found to be primarily distributed in the cytoplasm and was found to accelerate tumor progression by interacting with miR-141/200a (6). In cervical cancer, lncRNA SOX21-AS1 overexpression was found to inhibit cervical cancer progression, and its methylation was found to have clinical prognostic value (7). In prostate cancer, lncRNA SNHG7 was demonstrated to regulate tumor progression via the miR-324-3p/WNT2B axis (8).…”

Section: Introductionmentioning

confidence: 99%

lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR‑495‑3p/MYCBP axis

Qian

Garg

et al. 2020

Int J Oncol

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a tumor type characterized by high patient morbidity and mortality. It has been reported that long non-coding (lncRNA) LUNAR1 (LUNAR1) participates in the regulation of tumor progression, such as diffuse large B-cell lymphoma. However, its role and underlying mechanisms in CRC progression have not been elucidated. The present study was designed to investigate the underlying mechanisms by which LUNAR1 regulates CRC progression. RT-qPCR and Pearson's correlation analysis revealed that LUNAR1 was highly expressed and was negatively associated with the overall survival of CRC patients. Moreover, CCK-8, clone formation, wound-healing migration, Transwell chamber and FACs assay analyses showed that LUNAR1 knockdown inhibited CRC cell proliferation, migration and invasion, while accelerating cell apoptosis. Additionally, LUNAR1 was found to function as a sponge of miR-495-3p, which was predicted by TargetScan and confirmed by luciferase reporter assay. Furthermore, functional studies indicated that miR-495-3p overexpression inhibited CRC cell proliferation, migration and invasion, while accelerating cell apoptosis. In addition, bioinformatics and luciferase reporter assays showed that miR-495-3p was found to negatively target Myc binding protein (MYCBP), and functional research showed that LUNAR1 accelerated CRC progression via the miR-495-3p/MYCBP axis. In conclusion, LUNAR1 accelerates CRC progression via the miR-495-3p/MYCBP axis, indicating that LUNAR1 may serve as a prognostic biomarker for CRC patients.

show abstract

“…63 SOX21-AS1 has been linked to tumor progression and defined as a prognostic marker in cervical cancer, nephroblastoma, hepatocellular carcinoma, and lung and oral cancer. [64][65][66][67][68][69] In glioblastoma, SOX21-AS1 was defined along other four lncRNAs as a signature that predicts survival. 70 CRNDE is an important oncogenic lnRNA implicated in multiple malignancies including glioblastoma.…”

Section: Discussionmentioning

confidence: 99%

Proneural and mesenchymal glioma stem cells display major differences in splicing and lncRNA profiles

et al. 2020

View full text Add to dashboard Cite

Therapy resistance and recurrence in high-grade gliomas are driven by their populations of glioma stem cells (GSCs). Thus, detailed molecular characterization of GSCs is needed to develop more effective therapies. We conducted a study to identify differences in the splicing profile and expression of long non-coding RNAs in proneural and mesenchymal GSC cell lines. Genes related to cell cycle, DNA repair, cilium assembly, and splicing showed the most differences between GSC subgroups. We also identified genes distinctly associated with survival among patients of mesenchymal or proneural subgroups. We determined that multiple long noncoding RNAs with increased expression in mesenchymal GSCs are associated with poor survival of glioblastoma patients. In summary, our study established critical differences between proneural and mesenchymal GSCs in splicing profiles and expression of long non-coding RNA. These splicing isoforms and lncRNA signatures may contribute to the uniqueness of GSC subgroups, thus contributing to cancer phenotypes and explaining differences in therapeutic responses.

show abstract

Hypomethylation of the lncRNA SOX21-AS1 has clinical prognostic value in cervical cancer

Cited by 34 publications

References 49 publications

LINC01133 promotes hepatocellular carcinoma progression by sponging miR‐199a‐5p and activating annexin A2

LINC01133 promotes hepatocellular carcinoma progression by sponging miR‐199a‐5p and activating annexin A2

lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR‑495‑3p/MYCBP axis

Proneural and mesenchymal glioma stem cells display major differences in splicing and lncRNA profiles

Contact Info

Product

Resources

About